Posted in DefaultTag on Feb 23rd, 2016
How can we develop a deeper understanding of the regulation and activation of NRF2 in order to target therapies that depend on the inhibition of oxidative stress in a variety of disease states? Our latest podcast seeks an answer to this and more. Listen as Editor in Chief Irving H. Zucker (University of Nebraska Medical Center) interviews lead author Julian Lombard (Medical College of Wisconsin) and content expert Junie Paula Warrington (University of Mississippi Medical Center) about the innovative work by Priestley et al. Lombard and colleagues developed a NRF2 knockout rat to investigate the role of NRF2 in microvascular regulation in the context of a high-salt diet. What are the implications for the pathogenesis of hypertension? And how to “just right” levels of angiotensin 2 play a part in maintaining the NRF2 vs. oxidant stress balance? Listen and find out.
Jessica R. C. Priestley, Katie E. Kautenburg, Marc C. Casati, Bradley T. Endres, Aron M. Geurts, Julian H. Lombard The NRF2 knockout rat: a new animal model to study endothelial dysfunction, oxidant stress, and microvascular rarefaction Am J Physiol Heart Circ Physiol, published February 15, 2016. DOI: 10.1152/ajpheart.00586.2015.
Read Full Post »
Posted in DefaultTag on Feb 16th, 2016
Just what are the contributions of bombesin-like receptor 3 to blood pressure regulation? Listen as Associate Editor Debra I. Diz (Wake Forest University School of Medicine) interviews lead author Marc Reitman (National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health) and content expert Amy C. Arnold (Vanderbilt University) about the work by Lateef et al., which combined the use of genetic tools—a BRS-3 knockout mouse—as well as pharmacologic tools to explore the effect of this orphan receptor on blood pressure, filling a void in the literature about the physiology of BRS-3. This podcast tackles just about everything: “uncooperative” mice, effects on baroreflex sensitivity, and the controversial subject of pharmacological interventions for the treatment of obesity. Does the absence of evidence equate to “the evidence of absence”? Listen and find out.
Dalya M. Lateef, Cuiying Xiao, Robert J. Brychta, André Diedrich, Jurgen Schnermann, Marc L. Reitman Bombesin-Like Receptor 3 Regulates Blood Pressure and Heart Rate via a Central Sympathetic Mechanism Am J Physiol Heart Circ Physiol, published online January 22, 2016, DOI: 10.1152/ajpheart.00963.2015.
Read Full Post »
Posted in DefaultTag on Feb 4th, 2016
Riddle me this: if you were going to be stuck on an island with only one drug, which drug offers “the best bang for your buck” in controlling metabolic syndrome due to obesity? That’s just one question we tackle in this podcast about the translational work by Brooks et al on how metabolic syndrome in obesity affects the cerebral microvasculature, published as part of our Call for Papers on Small Vessels – Big Problems. Guest Editor Akos Koller (New York Medical College and University of Physical Education, Budapest, Hungary) interviews lead author Paul Chantler (West Virginia University) and content expert Julian Lombard (Medical College of Wisconsin) about the adaptions in cerebral circulation during the progression of metabolic syndrome using an obese Zucker rat model of human disease. How do pharmacological interventions aimed at treating major risk factors such as blood pressure and glucose levels affect cerebrovascular changes in metabolic syndrome? With metabolic syndrome affecting nearly 57 million adults in the U.S., you can’t afford not to listen to this engaging, insightful podcast.
Steven D. Brooks, Evan DeVallance, Alexandre C. d'Audiffret, Stephanie J. Frisbee, Lawrence E. Tabone, Carl D. Shrader, Jefferson C. Frisbee, Paul D. Chantler Metabolic syndrome impairs reactivity and wall mechanics of cerebral resistance arteries in obese Zucker rats Am J Physiol Heart Circ Physiol, published December 1, 2015, DOI: 10.1152/ajpheart.00691.2015.
Read Full Post »